Viewing data from:

TRANYLCYPROMINE SULFATE

ANDA

TRANYLCYPROMINE SULFATE | A040640 | STRIDES PHARMA INTERNATIONAL AG

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: PARNATE(TE code: AB)

Medicare Part D Spending

CMS annual spending data for Tranylcypromine Sulfate (2023)

Total Spending

$3.9M

Total Claims

10,992

Beneficiaries

1,773

Avg Cost/Unit

$1.64

Spending Trend

$5.1M(2019)→$4.4M(2020)→$4.3M(2021)→$4.3M(2022)→$3.9M(2023)

YoY Change:-9.1%

5yr CAGR:-6.5%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain2 active DMFs3 inactive

2 active API suppliers hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

TRIFARMA SPATRANYLCYPROMINE SULFATE

DMF 165222003

NURAY CHEMICALS PRIVATE LTDTRANYLCYPROMINE SULFATE USP

DMF 268082013

SMITH KLINE & FRENCH LABS DIV SMITHKLINE BECKMAN CORPInactiveTRANYLCYPROMINE SULFATE

DMF 46801982

ALCHYMARS SPAInactiveTRANYLCYPROMINE SULFATE USP

DMF 71321987

LONZA RIVERSIDEInactiveTRANYLCYPROMINE SULFATE

DMF 103171993

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Jul 13, 2006	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — EQ 10MG BASE

0 patents0 exclusivities▴

TABLET;ORAL | Approved: Jun 29, 2006

No patent or exclusivity listings for this strength.